Variables | Mutation (−) (n = 137) | Mutation (+) (n = 112) | p-value | ||
---|---|---|---|---|---|
LDLR null heterozygote (n = 25) | LDLR defective heterozygote (n = 52) | APOB/PCSK9 mutation (n = 37) | |||
Age, year | 51 ± 10 | 50 ± 12 | 47 ± 14 | 47 ± 14 | 0.099 |
Male, n (%) | 89 (65%) | 16 (64%) | 30 (57.7%) | 20 (54.1%) | 0.584 |
Xanthoma, n (%) | 5 (3.6%) | 1 (4%) | 11 (21.2%) | 2 (5.4%) | 0.001 |
CAD, n (%) | 114 (83.8%) | 21 (84%) | 42 (80.8%) | 32 (86.5%) | 0.911 |
Family history of CAD, n (%) | 62 (45.6%) | 12 (48%) | 23 (46%) | 15 (40.5%) | 0.935 |
Statin, n (%) | 123 (89.8%) | 17 (68%) | 38 (73.1%) | 32 (86.5%) | 0.005 |
TC, mmol/L | 6.51 ± 1.97 | 7.88 ± 1.55 | 7.14 ± 2.35 | 6.46 ± 2.06 | 0.007 |
HDL-C, mmol/L | 1.15 ± 0.3 | 1.05 ± 0.29 | 1.05 ± 0.35 | 1.09 ± 0.33 | 0.138 |
LDL-C, mmol/L | 4.63 ± 1.5 | 6.22 ± 1.48 | 5.47 ± 2.03 | 4.7 ± 1.5 | < 0.001 |
Untreated LDL-C, mmol/L | 7.5 ± 1.82 | 8.88 ± 1.82 | 7.94 ± 2.13 | 7.39 ± 1.56 | 0.004 |
Apo A, g/L | 1.4 ± 0.34 | 1.2 ± 0.26 | 1.23 ± 0.27 | 1.35 ± 0.34 | 0.002 |
Apo B, g/L | 1.37 ± 0.38 | 1.64 ± 0.37 | 1.55 ± 0.52 | 1.35 ± 0.41 | 0.003 |
TG, mmol/L | 1.72 (1.26–2.28) | 1.45 (1.18–1.88) | 1.59 (1.07–1.88) | 1.78 (1.51–2.14) | 0.032 |